KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Current Assets (2016 - 2025)

Boston Scientific (BSX) has disclosed Current Assets for 17 consecutive years, with $8.8 billion as the latest value for Q4 2025.

  • Quarterly Current Assets rose 27.08% to $8.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.8 billion through Dec 2025, up 27.08% year-over-year, with the annual reading at $8.8 billion for FY2025, 27.08% up from the prior year.
  • Current Assets hit $8.8 billion in Q4 2025 for Boston Scientific, up from $8.0 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $9.0 billion in Q2 2024 to a low of $5.1 billion in Q1 2022.
  • Historically, Current Assets has averaged $6.8 billion across 5 years, with a median of $6.5 billion in 2023.
  • Biggest five-year swings in Current Assets: dropped 24.79% in 2022 and later soared 52.75% in 2024.
  • Year by year, Current Assets stood at $6.3 billion in 2021, then decreased by 8.82% to $5.8 billion in 2022, then grew by 13.09% to $6.5 billion in 2023, then increased by 6.23% to $6.9 billion in 2024, then increased by 27.08% to $8.8 billion in 2025.
  • Business Quant data shows Current Assets for BSX at $8.8 billion in Q4 2025, $8.0 billion in Q3 2025, and $7.1 billion in Q2 2025.